Cochrane · systematic review · CD004389
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine
Galappaththy, GNL, Tharyan, P, Kirubakaran, R · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 12 · 66.7%Very low 1 · 5.6%Low 1 · 5.6%Moderate 2 · 11.1%High 2 · 11.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Primaquine five days compared to 14 days
Population: People with P. vivax malaria1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
P. vivax parasitaemia detected > 30 days after starting primaquine Primaquine five days vs 14 days | RR 10.05 [2.82, 35.86] | 2 studies · 186 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Serious adverse events Primaquine five days vs 14 days | no estimate extracted | 2 studies · 186 participants | Ungraded |
Other adverse events Primaquine five days vs 14 days | no estimate extracted | 2 studies · 186 participants | Ungraded |
Primaquine three days compared to 14 days
Population: People with P. vivax malaria1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
P. vivax parasitaemia detected > 30 days after starting primaquine Primaquine three days vs 14 days | RR 3.18 [2.1, 4.81] | 2 studies · 262 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Serious adverse events Primaquine three days vs 14 days | no estimate extracted | 2 studies · 262 participants | Ungraded |
Other adverse events Primaquine three days vs 14 days | no estimate extracted | 2 studies · 262 participants | Ungraded |
Primaquine seven days compared to 14 days
Population: People with P. vivax malaria1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
P. vivax parasitaemia detected > 30 days after starting primaquine Primaquine seven days vs 14 days | RR 2.24 [1.24, 4.03] | 1 study · 126 participants | Low Downgraded: imprecision, indirectness |
Severe adverse events Primaquine seven days vs 14 days | no estimate extracted | 1 study · 126 participants | Ungraded |
Other adverse events Primaquine seven days vs 14 days | no estimate extracted | 1 study · 126 participants | Ungraded |
Primaquine (weekly for eight weeks) compared to daily primaquine for 14 days
Population: Children and adults with blood smear positive P. vivax malaria1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
P. vivax parasitaemia detected > 30 days after starting primaquine Primaquine (weekly for eight weeks) vs daily primaquine | RR 2.97 [0.34, 25.87] | 1 study · 129 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events Primaquine (weekly for eight weeks) vs daily primaquine | no estimate extracted | 1 study · 129 participants | Ungraded |
Adverse events Primaquine (weekly for eight weeks) vs daily primaquine | no estimate extracted | 1 study · 129 participants | Ungraded |
Primaquine for five days
Population: People with P. vivax malaria1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
P. vivax parasitaemia detected > 30 days after starting primaquine | RR 0.98 [0.73, 1.3] | 4 studies · 2213 participants | High |
Serious adverse events | no estimate extracted | 4 studies · 2213 participants | Ungraded |
Other adverse events | no estimate extracted | 4 studies · 2213 participants | Ungraded |
Primaquine for 14 days
Population: People with P. vivax malaria1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
P. vivax parasitaemia detected > 30 days after starting primaquine | RR 0.6 [0.48, 0.75] | 10 studies · 1740 participants | High |
Serious adverse events | no estimate extracted | 10 studies · 1740 participants | Ungraded |
Other adverse events | no estimate extracted | 10 studies · 1740 participants | Ungraded |